deucravacitinib
bms
['psoriasis', 'deucrava', 'deucra', '$bmy', 'bristol']
$bmy bristol myers squibb announces new sotyktu (deucravacitinib) long-term data showing clinical efficacy maintained for up to two years with continuous treatment in moderate-to-severe plaque psoriasis stock news alerts in bio
Over 500 members. DM us for our premium stock alerts.